AM-Pharma has shown clinical Proof of Concept for treatment of Acute Kidney Injury with bovine Alkaline Phosphatase (bAP) in two separate Phase II trials.
Clinical Proof of Concept was also shown for treatment of severe Ulcerative Colitis in a Phase II trial with orally administered bAP.
Motivated by these positive results AM-Pharma is now fundraising to finance a switch to its proprietary recombinant human Alkaline Phosphatase (recAP) for further development in Acute Kidney Injury.
Once recAP has shown to be safe and effective in Phase II, AM-Pharma intends to find a Pharma partner for further development and worldwide marketing.

Web: www.AM-Pharma.com